PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2
Open Access
- 1 April 2016
- journal article
- Published by Elsevier in Cell Reports
- Vol. 15 (4) , 843-856
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growthGenes & Development, 2014
- Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activationNature Communications, 2013
- Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein KinaseMolecular Cell, 2012
- Loss of Tankyrase-Mediated Destruction of 3BP2 Is the Underlying Pathogenic Mechanism of CherubismCell, 2011
- PARP inhibitors in cancer: moving beyond BRCAThe Lancet Oncology, 2011
- Toward a unified nomenclature for mammalian ADP-ribosyltransferasesTrends in Biochemical Sciences, 2010
- Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteinsNature, 2008
- Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain lengthNucleic Acids Research, 2007
- Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signalGenes & Development, 2005
- MACROH2A2, a New Member of the MACROH2A Core Histone FamilyJournal of Biological Chemistry, 2001